Menetrier's disease

Current Treatment Options in Gastroenterology

Volumn 11, Issue 2, 2008, Pages 103-108

  Toubia, Nagib ^a   Schubert, Mitchell L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTIVIRUS AGENT; CETUXIMAB; DIDANOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GANCICLOVIR; GEFITINIB; IMIPENEM; MONOCLONAL ANTIBODY; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATULINE DEPOT; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABDOMINAL DISCOMFORT; ACNE; ALLERGIC REACTION; CENTRAL NERVOUS SYSTEM DISEASE; CHOLELITHIASIS; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONSTIPATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOSCOPIC BIOPSY; FEVER; FLATULENCE; GASTRECTOMY; HEART ARRHYTHMIA; HELICOBACTER PYLORI; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTHYROIDISM; INJECTION SITE PAIN; INTERSTITIAL LUNG DISEASE; LIVER FUNCTION TEST; LOADING DRUG DOSE; MALAISE; MENETRIER DISEASE; NAUSEA; NEUTROPENIA; PANCREATITIS; PATHOGENESIS; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SINUS BRADYCARDIA; THROMBOCYTOPENIA; VOMITING; WEAKNESS;

EID: 58649107846     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-008-0022-x     Document Type: Review

References (26)

1. Coffey RJ, Washington MK, Corless CL, Heinrich MC: Menetrier disease and gastrointestinal stromal tumors: Hyperproliferative disorders of the stomach. J Clin Invest 2007, 117:70-80.
2. Menetrier P: Des polyadenomes gastriques et de leurs rapports avec le cancer de l'estomac [in French]. Arch Physiol Norm Pathol 1888, 1:236-262.
3. Chen D, Aihara T, Zhao CM, et al.: Differentiation of the gastic mucosa. I. Role of histamine in control of function and integrity of oxyntic mucosa: Understanding gastric physiology through disruption of targeted genes. Am J Physiol Gastrointest Liver Physiol 2006, 291:G539-G544.
4. Krause DS, Van EtTen RA: Mechanisms of disease: tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
5. Bublil EM, Yarden YS The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007, 19:124-134.
6. Schubert ML, McCuen RW, Settle SL, Coffey RJ: Epidermal growth factor-related peptides regulate somatostatin, histamine, and gastrin secretion in human and rat stomach [abstract]. Gastroenterology 2003, 124:443.
7. Bluth RF, Carpenter HA, Pittelkow MR, et al.: Immunolocalization of transforming growth factor-alpha in normal and diseased human gastric mucosa. Hum Pathol 1995, 26:1333-1340.
8. Konstantinidou AE, Morphopoulos G, Korkolopoulou P, et al.: Menetrier disease of early infancy: A separate entity? J Pediatr Gastroenterol Nutr 2004, 39:177-182.
9. Dempsey PJ, Goldenring J, Soroka CJ, et al.: Possible role of transforming growth factor alpha in the pathogenesis of Menetrier's disease: Supportive evidence from humans and transgenic mice. Gastroenterology 1992, 103:1950-1963.
10. Geist M, Fich AE Mogle P: Menetrier's disease: evolution of disease under histamine-2 receptor antagonists. Am J Gastroenterol 1992, 87:648-650.
11. Ogawa T, Maeda K, Tonai S, et al.: Utilization of knockout mice to examine the potential role of gastric histamine H2-receptors in Menetrier's disease. J Pharmacol Sci 2003, 91:61-70.
12. Sferro TJ, Pawel BR, Quaiman SJ, Li BU: Menetrier disease of childhood: role of cytomegalovirus and transforming growth factor alpha. J Pediatr 1996, 128:213-219.
13. Kuzuya G, Kumada T, Kiriyama S, et al.: Contrast-enhanced ultrasonographic assessment of the response of Menetrier disease to Helicobacter pylori eradication therapy. J Ultrasound Med 2006, 25:1099-1103.
14. Bayerdörffer E, Ritter MM, Hatz R, et al.: Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori: is Helicobacter pylori a pathogenic factor in Menetrier's disease? Gut 1994, 35:701-704.
15. Madsen LG, Taskiran M, Madsen JL, Bytzer P: Menetrier's disease and Helicobacter pylori: Normalization of gastrointestinal protein loss after eradication therapy. Dig Dis Sci 1999, 44:2307-2312.
16. Meuwissen SG, Ridwan BU, Hasper HJ, Innemee G: Hypertrophic protein-losing gastropathy. Scand J Gastroenterol 1992, 27:1-7.
17. Wood GM, Bates C, Brown RC, Losowsky MS: Intramucosal carcinoma of the gastric antrum complicating Menetrier's disease. J Clin Pathol 1983, 36:1071-1075.
18. Ba-Ssalamah A, Prokop M, Uffmann M, et al.: Dedicated multidetector CT of the stomach: Spectrum of diseases. Radiographics 2003, 23:625-644.
19. Okanobu H, HataDJ, Haruma K, et al.: Giant gastric folds: differential diagnosis at US. Radiology 2003, 226:686-690.
20. Yeaton P, Frierson H: Octreotide reduces enteral protein losses in Menetrier's disease. Am J Gastroenterol 1993, 88:95-98.
21. Gadour MO, SalmAn AH, El Samman EE, Tadros NM: Menetrier's disease: an excellent response to octreotide. A case report from the Middle East. Trop Gastroenterol 2005, 26:129-131.
22. Green PT, Branch MS: Menetrier's disease treated with octreotide long-acting release. Gastrointest Endosc 2004, 60:1028-1029.
23. Burdick JS, Chung EK, Tanner G, et al.: Treatment of Menetrier's disease with a monoclonal antibody against the epidermal growth factor receptor. N Engl J Med 2000, 343:1697-1701.
24. Settle SH, Washington K, Lind C, et al.: Chronic treatment of Menetrier's disease with Erbitux: Clinical efficacy and insight into pathophysiology. Clin Gastroenterol Hepatol 2005, 3:654-659.
25. Hoffer V, Finkelstein Y, Balter J, et al.: Ganciclovir treatment in Menetrier's disease. Acta Paediatr 2003, 92:983-985.
26. Hubbard SR, Miller WTM Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 2007, 19:117-123.